Pfizer Signs $495M China Licensing Deal for Obesity Drug
Pfizer secured a $495 million licensing agreement with a Chinese biopharma partner to commercialize its obesity drug in mainland China. The deal includes an upfront payment plus milestone and royalty fees tied to sales performance over the agreement term.
1. Licensing Deal Details
Pfizer has granted a Chinese biopharma partner exclusive rights to develop, manufacture and commercialize its obesity therapy in mainland China under a $495 million agreement. The structure comprises an upfront payment to Pfizer and additional milestone and royalty fees based on regulatory milestones and future sales performance over the term of the contract.
Related News
FDS
Nvidia Q1 Revenue Soars 85% to $81.6B as Buyback Approved
FDS•
NVDA
NVIDIA Forecasts Zero China Data Center Revenue, Targets $20B Vera CPU Sales
NVDA•
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
TQQQ
ProShares 3x Nasdaq-100 ETF Gathers $31.3B, Hits 38.6% YTD Gain
TQQQ•
NVDA
Nvidia Q2 Profit Jumps 200% with Revenue Up 85%
NVDA•
Sources
F